Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a ...

Conferences are for institutional investors only. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI ...

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses ...

Fredrik Brag, CEO and Founder of Median Technologies, commented: "The past quarter has seen the successful culmination of a transformational period for the Company: we are beginning to see the ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company ...

Median Technologies has secured up to €47.5m ($49.9m) to support the regulatory filing and commercialisation efforts for its ...

Median Technologies has announced that the REALITY study of its AI/machine learning (ML) powered software as a medical device (SaMD) for lung cancer screening (LCS), eyonis LCS, has met the ...

About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses ...

Last month, Median said that it was preparing to file for FDA approval of iBiopsy for lung cancer screening, aiming at a green light for the SaMD before the end of 2023, based on study data ...

The eyonis® LCS SaMD is an AI-powered Software as a Medical Device (SaMD) to detect and diagnose (CADe/CADx) lung cancer in Low Dose Computed Tomography (LDCT) images. eyonis® LCS has met the primary ...

SOPHIA ANTIPOLIS, France, May 06, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company ...